JAK2 Specificity and Thrombosis Risk: Potential Role of Antiphospholipid Antibodies.

JAK2 Specificity and Thrombosis Risk: Potential Role of Antiphospholipid Antibodies. J Rheumatol. 2018 Nov 15;: Authors: Rothschild BM Abstract Janus kinase (JAK) inhibitors are a relatively new addition to our tools for treatment of rheumatoid arthritis (RA)1 They are responsible for transduction of more than 38 cytokinases2, with diffuse metabolic/immunologic implications. PMID: 30442832 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30442832?dopt=Abstract

Source: J Rheumatol - November 15, 2018 Category: Rheumatology Authors: Rothschild BM Tags: J Rheumatol Source Type: research